News | April 10, 2018

Thermo Fisher Scientific Enters Commercialization Agreement With Allecra Therapeutics GmbH

Source: Patheon, part of Thermo Fisher Scientific
Contact The Supplier
Swindon UK Aerial Shot

Thermo Fisher Scientific Inc., the world leader in serving science, is pleased to announce that it is entering into a manufacturing agreement with Allecra Therapeutics GmbH for the commercialization of Cefepime/AAI101. Allecra Therapeutics is a clinical stage biopharmaceutical company established in 2013 dedicated to the development of novel treatments to combat multi-drug resistant bacterial infections. AAI101 is an extended spectrum novel beta-lactamase inhibitor. When combined with well-established beta-lactam antibiotics, it will target serious resistant hospital infections including complicated urinary tract infections, complicated intra-abdominal infections and hospital acquired pneumonia.

The dedicated facility within Thermo Fisher’s Swindon, UK site will provide manufacturing solutions for Allecra’s clinical needs plus provide a manufacturing runway to commercialization to allow this important product to reach patients in need of effective treatment. The Swindon site has a successful history of providing alternative business models such as dedicated and condominium suites to companies wishing to progress their products to market and provide a sustainable commercial supply.

For more information about Thermo Fisher’s site at Swindon, please click here.

SOURCE: Patheon - Brand

Patheon, part of Thermo Fisher Scientific